Generic placeholder image

Mini-Reviews in Medicinal Chemistry


ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Farnesyltransferase Inhibitor as Anticancer Agent

Author(s): Anuj G. Agrawal and Rakesh R. Somani

Volume 9, Issue 6, 2009

Page: [638 - 652] Pages: 15

DOI: 10.2174/138955709788452702

Price: $65


Ras protein plays pivotal roles in control of normal and transformed cell growth. These ras genes are mutated in 30% of human cancer. For functioning of Ras protein its prenylation (farnesylation) is required. Therefore targeting Ras farnesylation is valuable approach for cancer treatment. Farnesyltransferase inhibitor (FTI) has been developed as anticancer drug and is currently evaluated in clinical trials. Different types of FTI have been identified that inhibit Ras farnesylation. FTI in combination with some cytotoxic antineoplastic drugs, exhibit additive effects.

Keywords: Farnesyltransferase, ras protein, farnesyltransferase inhibitor

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy